Sana Biotechnology, Inc. — Director's Dealing 2021

Feb 19, 2021

SEC Form 4/A — Form 4/A

Issuer: Sana Biotechnology, Inc. (SANA)
CIK: 0001770121
Period of Report: 2021-02-03

Reporting Person: REICIN ALISE (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-03	Stock Option (Right to Buy)	$25.00	A	11795	Acquired	2031-02-02	Common Stock (11795)	Direct

Footnotes

F1: This Form 4/A is being filed to correct a calculation error in regards to the number of option shares acquired.

F2: The stock option shall vest and become exercisable in full on February 3, 2022.